Mark Lohsen

Mark Lohsen has extensive experience in the field of biotechnology and gene therapy. Mark started their career as a Summer Undergraduate Research Intern at Stony Brook University in 2007, where they conducted experiments on genetic complementation of adenovirus genes. Mark then worked as a Summer Undergraduate Research Intern at Penn State College of Medicine in 2008, focusing on studying the interactions between viruses and host cells. Mark also worked as an Undergraduate Thesis Research Assistant at the National Cancer Institute (NCI) during the same year, where they amplified, sequenced, and analyzed DNA in search of mutations related to blindness and deafness in animals.

Moving forward, Mark joined Boston University in 2009 as a Research Assistant, assisting in investigations on bacterial outer membrane proteins and vaccine enhancement. In this role, they managed colony breeding and genotyping, as well as conducted immunization experiments with various vaccine adjuvants. Mark continued their research at Boston University as a Research Assistant from 2012 to 2015, focusing on genetic variants related to substance abuse and Alzheimer's disease. One of their notable discoveries was the link between genetic markers for cannabis dependence and schizophrenia.

In 2015, Mark joined 1Globe Health Institute as a Research Associate, specializing in gene-silencing technology using aiRNA. Their responsibilities included post-synthesis processing of RNA oligonucleotides, assessing gene silencing efficacy, and conducting mammalian cell transfection experiments.

Most recently, Mark has been working at Voyager Therapeutics, Inc. as an Associate Scientist and, later, as a Senior Associate Scientist. Their work involves maintaining mammalian cells for AAV gene therapy knockdown potency studies and determining AAV virus titers using qPCR and ddPCR techniques.

Overall, Mark Lohsen has a diverse background in biotechnology, with experience in gene-silencing, genetic variants, virus-host interactions, and mammalian cell transfection.

Mark Lohsen has a strong educational background in the field of Biochemistry. Mark completed their Bachelor of Science (B.S.) degree in Biochemistry and Molecular Biology at Gettysburg College from 2005 to 2009. Following this, they pursued further studies and obtained a Master of Arts (M.A.) degree in Biochemistry from Boston University, where they studied from 2009 to 2015.